Pfizer to Acquire Biohaven for ~$11.6B
Shots:
- Pfizer to acquire all outstanding shares of Biohaven for $148.50/share in cash making a total deal value of ~$11.6B, representing a premium of 78.6% to Biohaven's last closing price of $83.14. The transaction is expected to be close in early 2023
- Biohaven shareholders including Pfizer to receive 0.5 of a share of a new publicly-traded company (New Biohaven) that retains Biohaven’s non-CGRP pipeline compounds. The acquisition expands Pfizer’s pipeline for further growth through 2030 & beyond
- Biohaven’s CGRP programs include rimegepant & zavegepant for migraine. Additionally, New Biohaven to receive royalties from Pfizer for rimegepant & zavegepant in the US, if sales exceed ~$5.25B
Ref: Businesswire | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
